Agilent Technologies, Inc.

Agilent Technologies is a United States-based laboratory technology company headquartered in Santa Clara, California. It supplies analytical instruments, laboratory consumables, software, informatics, and lifecycle services to organizations that measure, characterize, manufacture, and quality-control chemical, biological, and clinical materials. Its customers include pharmaceutical and biopharmaceutical companies, chemical manufacturers, food and beverage producers, environmental laboratories, energy companies, hospitals and diagnostic laboratories, universities, government research institutions, and contract testing organizations. The company was established in 1999 when Hewlett-Packard separated several businesses into an independent public company. Agilent inherited important capabilities from HP's measurement, chemical analysis, instrumentation, optics, electronic components, medical equipment, and test-and-measurement operations. Its initial public offering raised approximately $2.1 billion and was described at the time as the largest IPO in Silicon Valley history. The new company initially had a substantially broader technology portfolio than it does today, including electronic measurement, semiconductor-related activities, optics, and laboratory and medical products. During the 2000s, Agilent divested or sold several non-core activities. Its health-care and medical-products organization was sold to Philips Medical Systems in 2001. It later sold its semiconductor integrated-circuit business, its interest in Lumileds, and its semiconductor test operations. These transactions gradually shifted the company toward laboratory analysis and life-science applications. The most consequential portfolio change came in 2014, when Agilent separated its electronic measurement business into Keysight Technologies. Agilent retained the life sciences, diagnostics, and applied markets businesses, while Keysight became the independent electronic measurement company. Agilent's current portfolio spans liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, electrophoresis, bioanalysis, cell analysis, genomics, pathology and diagnostics, sample preparation, automation, vacuum technologies, chromatography columns, chemical standards, reagents, and laboratory software. Its CrossLab organization provides instrument maintenance, asset management, laboratory optimization, compliance support, training, and other services. The combination of capital equipment with consumables, software, and recurring service is central to the company's laboratory workflow strategy. The company has expanded through acquisitions in cancer diagnostics, genomics, cell analysis, spectroscopy, laboratory informatics, and life-science instrumentation. It has also invested in digital laboratory tools, including remote technical support and connected laboratory-management capabilities. Agilent continues to serve international research and industrial markets while increasing its exposure to pharmaceutical manufacturing, biopharmaceutical development, clinical and molecular diagnostics, and nucleic-acid-based therapeutics. As of 2024, Padraig McDonnell is the company's chief executive officer, succeeding Mike McMullen.

Agilent Technologies originated in Hewlett-Packard's measurement, components, chemical-analysis, and medical businesses. HP announced in 1999 that these activities would be separated into a new company. Agilent was incorporated as the successor brand for the spin-off and completed an initial public offering on November 18, 1999. The offering raised approximately $2.1 billion and was characterized by Agilent as the largest IPO in Silicon Valley history at that point. The new company's name was intended to evoke agility, while its early slogan, "Innovating the HP Way," acknowledged the technical and managerial culture inherited from HP. Agilent did not initially operate as a narrowly defined laboratory company. Its inherited portfolio included electronic measurement, semiconductor testing, photonics, chemical analysis, and medical-related businesses. HP distributed its remaining Agilent shares to HP shareholders on June 2, 2000, making Agilent independent. The company subsequently reviewed its portfolio and divested or separated businesses that did not fit its long-term laboratory and scientific focus. A major transformation came through the Varian acquisition, completed in 2010. Varian brought analytical technologies and customer relationships that complemented Agilent's chromatography, spectroscopy, and laboratory offerings. In 2012, Agilent acquired Dako, a Danish company specializing in cancer diagnostics. Dako broadened Agilent's participation in pathology and oncology testing and helped establish diagnostics as one of the company's core markets. Agilent later separated its electronic-measurement business from the rest of the company. The separation was completed on November 1, 2014, with the electronic-measurement operations becoming Keysight Technologies. Agilent thereafter concentrated on life-science research, diagnostics, pharmaceutical and biopharmaceutical work, and applied chemical markets. Its business model increasingly combined instruments with columns, reagents, sample-preparation products, laboratory software, maintenance, training, and technical services. The modern Agilent portfolio covers gas chromatography, liquid chromatography, mass spectrometry, molecular and atomic spectroscopy, laboratory informatics, consumables, pathology products, and biopharmaceutical solutions. Customers include pharmaceutical and biotechnology organizations, academic and government laboratories, hospitals, contract laboratories, food and environmental testing organizations, and chemical manufacturers. The company sells through direct commercial channels and partners across international markets. Agilent's marketing and customer-development model is specialized and education-led. The company uses application notes, technical papers, webinars, training, product demonstrations, scientific conferences, trade shows, digital advertising, and professional social platforms to reach laboratory professionals. This communication style reflects the complexity of its products: purchasing decisions depend not only on brand awareness but also on analytical performance, method validation, compliance, interoperability, service availability, and total cost of ownership. In the 2020s, Agilent continued to expand beyond stand-alone instruments. Its strategy included workflow integration, laboratory automation, software, diagnostics, and biopharmaceutical manufacturing services. The announced BioVectra transaction in 2024 represented a move further into contract development and manufacturing, particularly in specialized therapeutic modalities. Agilent remains headquartered in Santa Clara, California, and is publicly traded on the New York Stock Exchange under the symbol A.

1. 2024BioVectra acquisition announced

   Agilent announced a transaction intended to expand its biopharmaceutical development and manufacturing capabilities.

   Source
2. 2014Keysight separation

   Agilent completed the separation of its electronic-measurement business into Keysight Technologies.

   Source
3. 2012Dako acquisition

   Agilent acquired Dako, strengthening cancer diagnostics and pathology offerings.

   Source
4. 2010Varian acquisition completed

   The Varian acquisition expanded Agilent's analytical-instrument and life-science capabilities.

   Source
5. 2000Agilent becomes independent from HP

   HP distributed its remaining Agilent ownership to HP shareholders on June 2, completing the separation.

   Source
6. 1999Agilent is established through an HP spin-off

   Hewlett-Packard announced the creation of Agilent from its measurement, components, chemical-analysis, and medical-related businesses.

   Source
7. 1999Initial public offering

   Agilent's November 18 IPO raised approximately $2.1 billion and set a Silicon Valley IPO record at the time.

   Source

Premium scientific-instrument and laboratory-workflow provider focused on dependable measurement, integrated analytical solutions, data integrity, regulatory support, and long-term service relationships.

• 8890 GCGas chromatography

  The 8890 GC is Agilent's high-end gas-chromatography platform for laboratories analyzing volatile and semi-volatile compounds. It is used in applications such as environmental testing, food analysis, petrochemical work, pharmaceutical testing, and forensic analysis. The platform is designed for repeatable separations, laboratory automation, method control, and integration with detectors and data systems.

• 6545 Q-TOFMass spectrometry

  The 6545 Q-TOF is a quadrupole time-of-flight mass spectrometer used for accurate-mass analysis, compound identification, screening, and research workflows. It can be paired with liquid-chromatography systems and is relevant to proteomics, metabolomics, pharmaceutical research, food testing, and other applications requiring high-resolution mass information.

• Cary 60 UV-VisMolecular spectroscopy

  The Cary 60 UV-Vis is an ultraviolet-visible spectrophotometer for quantitative and qualitative measurement of liquid and solid samples. It is used in research, education, pharmaceutical quality control, chemical analysis, and materials-related applications. The product represents Agilent's spectroscopy business and can be incorporated into routine laboratory workflows.

• HPLC and liquid-chromatography systemsLiquid chromatography

  Agilent's HPLC and liquid-chromatography portfolio includes systems, modules, detectors, columns, software, and accessories for separating and measuring compounds in complex samples. These systems are widely used in pharmaceutical development and quality control, food and environmental testing, chemical analysis, and academic research.

• Pathology and companion-diagnostics solutionsClinical diagnostics

  Agilent's diagnostics portfolio includes pathology products and companion-diagnostics technologies associated with cancer testing. These offerings support tissue analysis, biomarker assessment, and clinical or research workflows. The business traces a significant part of its expansion to the acquisition of Dako.

• 2018Agilent Companion Diagnostics Campaign

  Healthcare · Clinical diagnostics · Global

  Agilent and agency Flywheel developed integrated marketing materials for companion-diagnostics offerings, including print, digital, brochure, and training communications.

  Outcome. The campaign received an Integrated Award of Excellence at the 31st Annual Rx Club Show.

  Source
• Technical content and laboratory-workflow marketing

  Global · Life sciences · Applied chemical markets · Diagnostics

  Agilent uses application notes, scientific papers, webinars, training, conferences, trade shows, search marketing, professional social media, and targeted digital communications to educate specialist buyers and promote integrated laboratory workflows.

  Source

• 2024Acquisition of BioVectra announcedM&A

  Agilent sought to expand its biopharmaceutical development and manufacturing capabilities.

  What changed. Agilent announced an agreement to acquire BioVectra.

  Aftermath. The planned combination was intended to add capabilities in specialized therapeutic modalities, including oligonucleotides and CRISPR-related therapeutics.

  Source
• 2013Decision to separate electronic measurementStrategy

  Agilent determined that its electronic-measurement activities and laboratory-focused businesses would be better managed as separate companies.

  What changed. The company announced a separation that created Keysight Technologies.

  Aftermath. The separation was completed on November 1, 2014, leaving Agilent focused on life sciences, diagnostics, and applied markets.

  Source
• 2012Acquisition of DakoM&A

  Agilent wanted to expand in cancer diagnostics and pathology.

  What changed. Agilent acquired Dako, a Danish cancer-diagnostics company.

  Aftermath. The transaction strengthened Agilent's diagnostics and pathology business.

  Source
• 2010Acquisition of VarianM&A

  Agilent sought to broaden its analytical-instrument portfolio and strengthen its position in life-science and applied markets.

  What changed. Agilent completed the acquisition of Varian Inc.

  Aftermath. Varian's technologies and customer base became part of Agilent's analytical-solutions portfolio.

  Source
• 1999Spin-off from Hewlett-PackardStrategy

  HP sought to separate several technology businesses, including measurement and chemical-analysis activities, into a focused public company.

  What changed. Agilent was created and launched through a public offering in November 1999.

  Aftermath. The company became fully independent from HP in June 2000.

  IPO proceeds. Approximately US$2.1 billion raised (November 18, 1999)

  Source

• 2024Agilent announces acquisition of BioVectra

  Agilent announced the acquisition of BioVectra, a contract development and manufacturing organization, to expand capabilities in areas including oligonucleotides and CRISPR-related therapeutics.

  M&A
  Source
• 2024Padraig McDonnell succeeds Mike McMullen as CEO

  Agilent appointed Padraig McDonnell chief executive officer on May 1, 2024.

  Leadership change
  Source
• 2020Agilent introduces CrossLab Virtual Assist

  The mobile application provided remote technical-support capabilities for laboratory instruments and workflows.

  Product launch
  Source
• 2019Agilent acquires BioTek Instruments

  The acquisition expanded Agilent's life-science instrumentation business into microplate-based cellular analysis and related workflows.

  M&A
  Source
• 2018Agilent diagnostics campaign receives Rx Club recognition

  A companion-diagnostics marketing campaign developed by Agilent and Flywheel received an Integrated Award of Excellence at the Rx Club Show.

  Campaign
  Source
• 2018Agilent announces multiple life-science acquisitions

  The company acquired or announced acquisitions involving Luxcel Biosciences, Lasergen, Genohm, Ultra Scientific, AATI, ProZyme, Young In Scientific, and ACEA Biosciences.

  M&A
  Source
• 2016Agilent acquires Cobalt Light Systems

  The purchase added Raman spectroscopy technology and broadened Agilent's spectroscopy offering.

  M&A
  Source
• 2016Agilent expands genomics and laboratory-information portfolio

  Agilent acquired Multiplicom, strengthening capabilities related to molecular diagnostics and genomic analysis.

  M&A
  Source
• 2015Agilent agrees to acquire Seahorse Bioscience

  The acquisition added cellular metabolism and bioenergetics analysis capabilities to Agilent's life-science portfolio.

  M&A
  Source
• 2014Agilent and Keysight complete separation

  Agilent completed the separation of its electronic-measurement operations into Keysight Technologies, concentrating Agilent on life sciences, diagnostics, and applied markets.

  M&A
  Source
• 2014Agilent completes Keysight separation

  The formal separation transferred Agilent's electronic measurement business to Keysight, leaving Agilent focused on life sciences, diagnostics, and applied markets.

  M&A
  Source
• 2014Agilent exits nuclear magnetic resonance business

  The company announced its decision to leave the nuclear magnetic resonance business as part of its portfolio focus.

  Other
  Source
• 2013Agilent announces separation of Keysight

  Agilent announced that its electronic measurement operations would become a separate public company called Keysight Technologies.

  M&A
  Source
• 2012Agilent acquires Dako

  Agilent acquired Danish cancer-diagnostics company Dako, adding pathology and oncology-related capabilities to its portfolio.

  M&A
  Source
• 2012Agilent agrees to acquire Dako

  The acquisition of Danish cancer-diagnostics company Dako expanded Agilent's presence in pathology and life-science diagnostics.

  M&A
  Source
• 2010Agilent completes acquisition of Varian

  Agilent completed its acquisition of Varian, expanding its analytical-instrument portfolio and strengthening its presence in life-science and applied chemical markets.

  M&A
  Source
• 2005Agilent announces semiconductor business divestitures

  Agilent announced the sale of its semiconductor integrated-circuit business and the separation of its semiconductor test operations, accelerating its move away from electronics manufacturing.

  M&A
  Source
• 2005Agilent sells Lumileds stake to Philips

  Agilent sold its remaining interest in LED manufacturer Lumileds to Philips.

  M&A
  Source
• 2001Agilent sells health-care and medical-products organization to Philips

  The transaction removed a major medical-products activity from Agilent's portfolio during its early restructuring.

  M&A
  Source
• 1999Agilent Technologies is spun off from Hewlett-Packard

  Agilent began operating as an independent public company after HP separated several measurement, instrumentation, optics, electronics, and medical businesses.

  M&AOther
  Source

1. Agilent Technologies official website
2. Agilent company history
3. Agilent history timeline: 1999
4. Agilent Technologies
5. Agilent diagnostics campaign wins an award
6. Agilent shareholder resources and Varian acquisition information
7. Technical content and laboratory-workflow marketing